

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

|              |  |        |  |
|--------------|--|--------|--|
| NEWS         | 1  |        | Web Page URLs for STN Seminar Schedule - N. America  |
| NEWS         | 2  |        | "Ask CAS" for self-help around the clock   |
| NEWS         | 3  | DEC 18 | CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role         |
| NEWS         | 4  | DEC 18 | CA/CAPLUS patent kind codes updated  |
| NEWS         | 5  | DEC 18 | MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000                   |
| NEWS         | 6  | DEC 18 | MEDLINE updated in preparation for 2007 reload   |
| NEWS         | 7  | DEC 27 | CA/CAPLUS enhanced with more pre-1907 records  |
| NEWS         | 8  | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals                                  |
| NEWS         | 9  | JAN 16 | CA/CAPLUS Company Name Thesaurus enhanced and reloaded                                     |
| NEWS         | 10   | JAN 16 | IPC version 2007.01 thesaurus available on STN   |
| NEWS         | 11   | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data                               |
| NEWS         | 12   | JAN 22 | CA/CAPLUS updated with revised CAS roles   |
| NEWS         | 13   | JAN 22 | CA/CAPLUS enhanced with patent applications from India                                     |
| NEWS         | 14   | JAN 29 | PHAR reloaded with new search and display fields   |
| NEWS         | 15   | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases             |
| NEWS         | 16   | FEB 15 | PATDPASPC enhanced with Drug Approval numbers  |
| NEWS         | 17   | FEB 15 | RUSSIAPAT enhanced with pre-1994 records   |
| NEWS         | 18   | FEB 23 | KOREAPAT enhanced with IPC 8 features and functionality                                    |
| NEWS         | 19   | FEB 26 | MEDLINE reloaded with enhancements   |
| NEWS         | 20   | FEB 26 | EMBASE enhanced with Clinical Trial Number field   |
| NEWS         | 21   | FEB 26 | TOXCENTER enhanced with reloaded MEDLINE   |
| NEWS         | 22   | FEB 26 | IFICDB/IFIPAT/IFIUDB reloaded with enhancements  |
| NEWS         | 23   | FEB 26 | CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases |
| NEWS         | 24   | MAR 15 | WPIDS/WPIX enhanced with new FRAGHITSTR display format                                     |
| NEWS         | 25   | MAR 16 | CASREACT coverage extended   |
| NEWS         | 26   | MAR 20 | MARPAT now updated daily   |
|              |  |        |  |
| NEWS EXPRESS | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. |        |  |
|              |  |        |  |
| NEWS HOURS   | STN Operating Hours Plus Help Desk Availability  |        |  |
| NEWS LOGIN   | Welcome Banner and News Items  |        |  |
| NEWS IPC8    | For general information regarding STN implementation of IPC 8  |        |  |
| NEWS X25     | X.25 communication option no longer available  |        |  |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:27:21 ON 21 MAR 2007

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'PCTFULL' ENTERED AT 08:27:29 ON 21 MAR 2007

COPYRIGHT (C) 2007 Univentio

FILE LAST UPDATED: 20 MAR 2007

<20070320/UP>

MOST RECENT UPDATE WEEK: 200711

<200711/EW>

FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s WO 0071135/pn

L1 0 WO 0071135/PN  
(WO71135/PN)

=> s WO 200071135/pn

L2 1 WO 200071135/PN  
(WO2000071135/PN)

=> s 12 and leukemia

28368 LEUKEMIA

8889 LEUKEMIAS

30306 LEUKEMIA

(LEUKEMIA OR LEUKEMIAS)

L3 1 L2 AND LEUKEMIA

=> s 13 and lympho?

56381 LYMPHO?

L4 1 L3 AND LYMPHO?

=> d ibib kwic

L4 ANSWER 1 OF 1

PCTFULL COPYRIGHT 2007 Univentio on STN

ACCESSION NUMBER:

2000071135 PCTFULL ED 20020515

TITLE (ENGLISH):

ANTI-TUMOR COMPRISING BOROPROLINE COMPOUNDS

TITLE (FRENCH):

AGENTS ANTI-TUMORALES CONTENANT DES COMPOSES DE

BOROPROLINE

INVENTOR(S):

WALLNER, Barbara, P.;

MILLER, Glenn

PATENT ASSIGNEE(S):

POINT THERAPEUTICS, INC.

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER

KIND

DATE

WO 2000071135

A1 20001130

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ  
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS  
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN  
MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR  
TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK  
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM  
GA GN GW ML MR NE SN TD TG

PRIORITY INFO.:

US 1999-60/135,861

19990525

APPLICATION INFO.: WO 2000-US14505 A 20000525  
PI WO 2000071135 A1 20001130

DETD . . . who have normal  
hemopoietic activity. In another embodiment, the subject is HIV  
negative. In certain  
embodiments, the subjects are not myeloid or lymphoid  
suppressed or are not candidates for  
treatment with an agent which causes such suppression at the time of  
treatment with the  
methods. . . .

.  
carcinoma, hypernephroid  
carcinoma, infantile embryonal carcinoma, carcinoma in situ,  
intraepidermal carcinoma,  
intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell  
carcinoma, lenticular  
carcinoma, carcinoma lenticulare, lipomatous carcinoma,  
lymphoepithelial carcinoma,  
carcinoma mastitoides, carcinoma medullare, medullary carcinoma,  
carcinoma melanodes,  
melanotic carcinoma, mucinous carcinoma, carcinoma muciparum, carcinoma  
mucocellulare,  
mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, . . .

As used herein, the terms hemopoietic and hematopoietic are used  
interchangeably to  
mean all blood cells including myeloid and lymphoid cells.  
Myeloid cells include  
erythrocytes (i.e., red blood cells), macrophages, monocytes,  
granulocytes including  
neutrophils, eosinophils and basophils, mast cells, megakaryocytes,  
platelets and dendritic  
cells, and lymphoid cells include T and B lymphocytes  
, thymic dendritic cells and natural  
killer (NK) cells. Hemopoietic stimulation, as used herein, refers to  
the increase in  
hemopoietic cell numbers or. . . .

.  
); for eosinophils 0-700 per [d] (mean - 150); for  
macrophages and monocytes 200-950 per [t] (mean -430); for  
lymphocytes 1500-4000 per [L] (mean -2500); for erythrocytes  $4.2 \times 10^6 - 6.1 \times 10^6$  per [t]; and for  
platelets  $13 \times 10^9$  per [L]. . . .

.  
at between 500 and 1000 per [L] and  
severe neutropenia at below 500 per [d]. Likewise, in adults, a  
lymphocyte count at less than  
1500 is considered a medically undesirable condition. In children, the  
value is less than  
3000. Other preselected values. . . .

.  
used interchangeably. An example of an  
immunocompromised subject is one infected with HIV and experiencing  
AIDS-related  
symptoms such as low CD4+ T lymphocyte levels. In still other  
embodiments, the methods  
may be used in subjects who are HIV-positive and who may be  
immunocompromised,  
provided that. . . .

Thus in certain embodiments, the subjects are not myeloid or  
lymphoid suppressed or  
are not candidates for treatment with an agent which causes such  
suppression at the time of

treatment with the methods. . . in myeloid cells such as erythrocytes, neutrophils or platelets, to below protective or normal levels. Exemplary myelosuppressed conditions are hennopoietic malignancies, including leukemia and lymphoma and diseases such as chronic idiopathic neutropenia, cyclic neutropenia, anemia and thrombocytopenia. Similarly, lymphoid suppressing conditions are those which induce a reduction in lymphoid cells such as T lymphocytes. Suppression of lymphoid cells or some myeloid cells such as granulocytes is also referred to as immunosuppression since reduction in these cell types makes an individual susceptible to, inter alia, infection. Subjects may be exposed to myeloid, lymphoid or general immune suppressing conditions by the use of either immunosuppressant drugs such as cyclosporin or high dose chemotherapeutic compounds which.

iobenguane; lododoxorubicin; lporneanol, 4-; irinotecan; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide + estrogen + progesterone; leuprorelin; levarnisole; liarozole; linear polyarnine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; . . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

|                      |            |         |
|----------------------|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL   |
| FULL ESTIMATED COST  | ENTRY      | SESSION |
|                      | 8.42       | 8.63    |

STN INTERNATIONAL LOGOFF AT 08:29:46 ON 21 MAR 2007